(2,5-二甲基-3-呋喃)甲醇 | 1003-96-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 中文名称: (2,5-二甲基-3-呋喃)甲醇
• 英文名称: 2,5-dimethyl-3-(hydroxymethyl)furan
• 英文别名: (2,5-Dimethyl-3-furyl)methyl alcohol；3-hydroxymethyl-2,5-dimethylfuran；(2,5-dimethyl-furan-3-yl)carbinol；(2,5-dimethyl-furan-3-yl)-methanol；(2,5-Dimethylfuran-3-yl)methanol
• CAS: 1003-96-9
• 化学式: C₇H₁₀O₂
• mdl: MFCD11646256
• 分子量: 126.155
• InChiKey: YZKVNZQOYBRCPL-UHFFFAOYSA-N

物化性质

• 沸点：
  89-90 °C(Press: 10 Torr)
• 密度：
  1.0483 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  33.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2932190090

反应信息

• 作为反应物：
  描述：

  (2,5-二甲基-3-呋喃)甲醇 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以56%的产率得到2,5-dimethyl-3-furaldehyde
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST

  摘要：

  公开号：

  EP2210876B1
• 作为产物：
  描述：

  2,5-二甲基-3-呋喃甲酰氯 在 sodium tetrahydroborate 、 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 以100%的产率得到(2,5-二甲基-3-呋喃)甲醇
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST

  摘要：

  公开号：

  EP2210876B1

文献信息

• Arylalkylether and arylalkylthioether inhibitors of lipoxygenase enzyme
  申请人：Abbott Laboratories

  公开号：US05183818A1

  公开（公告）日：1993-02-02

  The present invention provides compounds having the structure Y-Het-[Q.sub.1 ]-X-[Q.sub.2 ]-Z which inhibit the catalytic action of lipoxygenase enzymes, particularly 5-lipoxygenase, and thereby reduce the biosynthesis of leukotrienes B.sub.4, C.sub.4, D.sub.4, and E.sub.4. In the generic formula given above, X is oxygen or sulfur and Het is a heteroaryl group selected from the group consisting of furyl, thienyl, 2-, 3-, and 4-pyridyl, 2- and 3-benzo[b]furyl, 2- and 3-benzo[b]thienyl and thienothienyl. Y is one or two substituents independently selected from hydrogen, hydroxy, halogen, cyano, alkyl, haloalkyl, alkoxy, alkylthio, alkoxyaryl), alkylthioaryl, arylalkoxy, arylalkylthio, aryloxy, arylthio, alkylamido, cycloalkyl, alkanoyl, alkoxycarbonyl, amino, alkylamino, dialkylamino, and the following groups wherein R, at each occurrence, is independently selected from hydrogen and alkyl of from one to six carbon atoms: --CRROR, --NRC(O)R, --NRC(O)OR, and --C(O)NRR. The group Q.sub.1 is absent or is divalent alkylene of from one to six carbon atoms, and Q.sub.2 is divalent alkylene from from two to ten carbon atoms. The group Z is N(OR.sub.1)COR.sub.2 where R.sub.1 is selected from hydrogen or a pharmaceutically suitable salt. R.sub.2 is selected from hydrogen; alkyl; cycloalkyl; amino; alkylamino, optionally substituted by hydroxyl, halogen, alkoxy or carboxyl; dialkylamino in which the alkyl groups are independently are optionally substituted by hydroxyl, halogen, alkoxy or carboxyl; cycloalkylamino; 2-hydroxyethylamino; N-morpholino; N-thiomorpholino; N-piperazine; N'-alkyl-N-piperazine and cyclopropylmethylamino.

  本发明提供了具有结构Y-Het-[Q.sub.1]-X-[Q.sub.2]-Z的化合物，可以抑制脂氧合酶酶的催化作用，特别是5-脂氧合酶，并从而减少白三烯B.sub.4、C.sub.4、D.sub.4和E.sub.4的生物合成。在上述通用公式中，X为氧或硫，Het为从呋喃基、噻吩基、2-、3-和4-吡啶基、2-和3-苯并[b]呋喃基、2-和3-苯并[b]噻吩基和噻吩噻吩基中选择的杂环芳基。Y是一个或两个独立选择自氢、羟基、卤素、氰基、烷基、卤代烷基、烷氧基、烷硫基、烷氧基芳基、烷硫基芳基、芳基烷氧基、芳基烷硫基、芳氧基、芳硫基、烷基酰胺、环烷基、烷酰基、烷氧羰基、氨基、烷基氨基、二烷基氨基和以下基团的其中之一的取代基，其中R在每次出现时，独立选择自氢和碳原子数为一到六的烷基：--CRROR、--NRC(O)R、--NRC(O)OR和--C(O)NRR。基团Q.sub.1为缺失或为碳原子数为一到六的二价烷基，Q.sub.2为碳原子数为二到十的二价烷基。基团Z为N(OR.sub.1)COR.sub.2，其中R.sub.1选择自氢或药学适用的盐。R.sub.2选择自氢、烷基、环烷基、氨基、烷基氨基（可选择性地被羟基、卤素、烷氧基或羧基取代）、二烷基氨基，其中烷基基团可独立地被羟基、卤素、烷氧基或羧基取代、环烷基氨基、2-羟乙基氨基、N-吗啉基、N-硫吗啉基、N-哌嗪基、N'-烷基-N-哌嗪基和环丙甲基氨基。
• Furan and pyrrole containing lipoxygenase inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US05112848A1

  公开（公告）日：1992-05-12

  Substituted furan and pyrrole compounds which are useful in inhibiting lipoxygenase enzymes, particularly 5-lipoxygenase.

  替代呋喃和吡咯化合物可用于抑制脂氧合酶酶，特别是5-脂氧合酶。
• Compounds and methods for the treatment of pain
  申请人：——

  公开号：US20030153572A1

  公开（公告）日：2003-08-14

  Compounds according to structural diagram I are disclosed; 1 wherein R 1 , A and D are as defined in the specification. Also disclosed are methods for treating pain comprising administration of a pain-ameliorating effective amount of a compound in accord with structural diagram I and pharmaceutical compositions comprising a pain-ameliorating effective amount of a compound in accord with structural diagram I.

  公开了根据结构图I的化合物；其中R1，A和D的定义如规范中所述。还公开了治疗疼痛的方法，包括给予符合结构图I的化合物的缓解疼痛有效量的管理，并且包括符合结构图I的化合物的缓解疼痛有效量的制药组合物。
• Heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08309580B2

  公开（公告）日：2012-11-13

  The present invention provides a heterocyclic compound represented by the following formula (I), which has a glucagon antagonistic action and is useful for the prophylaxis or treatment of diabetes and the like, a compound represented by wherein ring A is an optionally substituted benzene ring and the like; Y is a nitrogen atom and the like; X is —O— and the like; R4 is a hydrogen atom and the like; R5 and R6 are each independently a hydrogen atom and the like; R1 is an optionally substituted hydrocarbon group and the like; R2 is a hydrogen atom and the like; and R3 is —(CH2)3—COOH and the like, or a salt thereof.

  本发明提供了一种杂环化合物，其由以下式子（I）表示，具有葡萄糖升高素拮抗作用，用于预防或治疗糖尿病等疾病，其中化合物由以下表示： 其中环A是可选取代的苯环等；Y是氮原子等；X是—O—等；R4是氢原子等；R5和R6各自独立地是氢原子等；R1是可选取代的烃基等；R2是氢原子等；R3是—（CH2）3—COOH等，或其盐。
• HETEROCYCLIC COMPOUND
  申请人：Banno Yoshihiro

  公开号：US20100256156A1

  公开（公告）日：2010-10-07

  The present invention provides a heterocyclic compound represented by the following formula (I), which has a glucagon antagonistic action and is useful for the prophylaxis or treatment of diabetes and the like, a compound represented by wherein ring A is an optionally substituted benzene ring and the like; Y is a nitrogen atom and the like; X is —O— and the like; R 4 is a hydrogen atom and the like; R 5 and R 6 are each independently a hydrogen atom and the like; R 1 is an optionally substituted hydrocarbon group and the like; R 2 is a hydrogen atom and the like; and R 3 is —(CH 2 ) 3 —COOH and the like, or a salt thereof.

  本发明提供了一种由以下式（I）表示的杂环化合物，该化合物具有葡萄糖高升素拮抗作用，并可用于预防或治疗糖尿病等疾病，其中，式中环A为可选取代苯环等；Y为氮原子等；X为—O—等；R4为氢原子等；R5和R6各自独立地为氢原子等；R1为可选取代的碳氢基团等；R2为氢原子等；R3为—（CH2）3—COOH等，或其盐。